Last reviewed · How we verify
RBV(24 weeks)
Ritonavir is a protease inhibitor used to treat HIV/AIDS by preventing the replication of the virus.
Ritonavir is a protease inhibitor used to treat HIV/AIDS by preventing the replication of the virus. Used for Treatment of HIV-1 infection in combination with other antiretroviral agents.
At a glance
| Generic name | RBV(24 weeks) |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Drug class | protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ritonavir works by binding to the protease enzyme of the HIV virus, preventing it from replicating and thereby reducing the viral load in the body. This mechanism of action is specific to the protease enzyme and is a key target in the treatment of HIV/AIDS.
Approved indications
- Treatment of HIV-1 infection in combination with other antiretroviral agents
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
Key clinical trials
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients (PHASE3)
- Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC) (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy (PHASE3)
- Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C (PHASE3)
- Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients (PHASE3)
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RBV(24 weeks) CI brief — competitive landscape report
- RBV(24 weeks) updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI